Steinbach Christina, Merchant Almas, Zaharie Alexandru-Teodor, Horak Peter, Marhold Maximilian, Krainer Michael
Internal Medicine I, Department of Oncology, Medical University of Vienna, 1090 Vienna, Austria.
Department of Radiation Oncology, Medical University of Vienna, 1090 Vienna, Austria.
Cancers (Basel). 2022 Nov 21;14(22):5719. doi: 10.3390/cancers14225719.
Recently, the development of immunotherapies such as cellular therapy, monoclonal antibodies, vaccines and immunomodulators has revolutionized the treatment of various cancer entities. In order to close the existing gaps in knowledge about cellular immunotherapy, specifically focusing on the chimeric antigen receptors (CAR) T-cells, their benefits and application in clinical settings, we conducted a comprehensive systematic review. Two co-authors independently searched the literature and characterized the results. Out of 183 records, 26 were considered eligible. This review provides an overview of the cellular immunotherapy landscape in treating prostate cancer, honing in on the challenges of employing CAR T-cell therapy. CAR T-cell therapy is a promising avenue for research due to the presence of an array of different tumor specific antigens. In prostate cancer, the complex microenvironment of the tumor vastly contributes to the success or failure of immunotherapies.
近年来，细胞疗法、单克隆抗体、疫苗和免疫调节剂等免疫疗法的发展彻底改变了各种癌症实体的治疗方式。为了填补细胞免疫疗法现有知识空白，特别是聚焦嵌合抗原受体（CAR）T细胞、其益处及在临床环境中的应用，我们进行了全面的系统综述。两位共同作者独立检索文献并对结果进行了描述。在183条记录中，26条被认为符合要求。本综述概述了细胞免疫疗法在治疗前列腺癌方面的情况，重点关注采用CAR T细胞疗法所面临的挑战。由于存在一系列不同的肿瘤特异性抗原，CAR T细胞疗法是一个很有前景的研究方向。在前列腺癌中，肿瘤复杂的微环境在很大程度上决定了免疫疗法的成败。
